Global Times: How to care for tens of thousands of seniors in remote mountain villages? This county in East China has a solution
BEIJING, July 25, 2025 /PRNewswire/ -- Life has never been happier for Xu Furong. The 86-year-old resident of Nanliuzhuang village starts each morning with a bit of light housework. Then, hand in hand with her 90-year-old husband, she walks for about 10 minutes, crossing two streets to reach the "senior canteen," which offers elderly residents convenient services at the "Yiyuanhong" Happy...
Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering
NANJING, China, July 25, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) under the stock code "09887". The clinical-stage biotech company priced its IPO at HKD 35 per share, offering 36.86 million shares (excluding green shoe option). The...
Colorcon Celebrates Grand Opening of New Manufacturing Facility in Malaysia
Johor plant is Colorcon's 7th major film coating plant and 16th manufacturing facility worldwide HARLEYSVILLE, Pa. and JOHOR, Malaysia, July 24, 2025 /PRNewswire/ -- Colorcon, a global leader of film coating systems, specialty excipients, controlled release formulations and controlled atmosphere packaging for the pharmaceutical and nutraceutical industries, today announced the grand opening...
Angel Yeast Showcases Innovative Yeast Protein at 2025 IFT FIRST in Chicago
CHICAGO, July 24, 2025 /PRNewswire/ -- The 2025 IFT FIRST (Food Improved by Research, Science, and Technology), one of the world's largest food science and innovation expos, recently took place from July 13 to 16 in Chicago. At the expo, Angel Yeast (SHA:600298) showcased its comprehensive, innovative lineup of yeast protein, yeast extract...
NYSE Content Advisory: Pre-Market update + McGraw Hill, Accelerant IPO on NYSE
NEW YORK, July 24, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market update + McGraw Hill, Accelerant IPO on NYSE...
AMSC Malaysia 2025 Set to Spotlight World-Class Expertise and Innovation in Aesthetic Medicine and Surgery
KUALA LUMPUR, Malaysia, July 24, 2025 /PRNewswire/ -- The Aesthetic Medicine & Surgery Conference & Exhibition (AMSC) returns for its fourth edition from August 6-7, 2025, with an expanded focus on global participation and advanced education. Held at the Kuala Lumpur Convention Centre (KLCC), AMSC 2025 will feature over 160 world-class speakers, 200 international brands, and 20 supporting partners, including 13...
OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology
BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced it has signed a term sheet ("Term Sheet") with Woori IO Co., Ltd. ("WORIO"), a South Korean medical device company developing next-generation noninvasive glucose monitoring technology....
Fapon at ADLM 2025: One-stop IVD Solutions & Deepened US Commitment
CHICAGO, July 24, 2025 /PRNewswire/ -- Fapon, a global leader in life sciences, will unveil its innovative one-stop IVD solutions at ADLM 2025, from July 29 to 31 in Chicago, IL. Fapon aims to be the trusted global partner for laboratories and IVD manufacturers with advanced innovations and dedicated localization services for...
Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer
HONG KONG, July 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial (AK112-310/HARMONi-GI2) of ivonescimab, a first-in-class PD-1/VEGF bispecific antibody developed by the company. The trial is investigating ivonescimab in combination with chemotherapy, with or without ligufalimab (CD47...
Scaling Self-Care Can Be a Game-Changer in Global Fight Against Non-Communicable Diseases
Ahead of the upcoming UN General Assembly to set a new vision for non-communicable diseases, the Global Self-Care Federation is calling for self-care strategies to be integrated into health plans Non-communicable diseases account for 76% of global deaths, and their impact continues to rise Current self-care activities are generating substantial global monetary savings ($119 billion per year) as...
